JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB141356

Ruxolitinib, ATP-competitive JAK1/2 inhibitor

Be the first to review this product! Submit a review

|

(3 Publications)

MW 306.4 Da, Purity >99%. Potent, selective ATP-competitive Janus-associated kinase 1 and 2 inhibitor (IC50 values of 3.3, 2.8 and 428 nM for JAK1, JAK2 and JAK3 respectively in vitro). Inhibits IL-6 signaling (IC50 = 281nM). Orally bioavailable.

Key facts

CAS number

941678-49-5

Purity

>99%

Form

Solid

form

Molecular weight

306.4 Da

Molecular formula

C<sub>1</sub><sub>7</sub>H<sub>1</sub><sub>8</sub>N<sub>6</sub>

PubChem

25126798

Nature

Synthetic

Solubility

Soluble in DMSO to 16 mM

Soluble in ethanol to 32 mM

Biochemical name

Ruxolitinib

Biological description

Potent, selective ATP-competitive Janus-associated kinase 1 and 2 inhibitor (IC50 values of 3.3, 2.8 and 428 nM for JAK1, JAK2 and JAK3 respectively in vitro). Inhibits IL-6 signaling (IC50 = 281nM). Orally bioavailable.

Canonical smiles

C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

Isomeric smiles

C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

InChi

InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1

InChiKey

HFNKQEVNSGCOJV-OAHLLOKOSA-N

IUPAC Name

(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Product protocols

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Cell reports. Medicine 5:101498 PubMed38569555

2024

Oncostatin M signaling drives cancer-associated skeletal muscle wasting.

Applications

Unspecified application

Species

Unspecified reactive species

Aylin Domaniku-Waraich,Samet Agca,Batu Toledo,Melis Sucuoglu,Sevgi Döndü Özen,Sevval Nur Bilgic,Dilsad Hilal Arabaci,Aynur Erkin Kashgari,Serkan Kir

Neural regeneration research 17:2029-2035 PubMed35142693

2022

Ruxolitinib attenuates secondary injury after traumatic spinal cord injury.

Applications

Unspecified application

Species

Unspecified reactive species

Zhan-Yang Qian,Ren-Yi Kong,Sheng Zhang,Bin-Yu Wang,Jie Chang,Jiang Cao,Chao-Qin Wu,Zi-Yan Huang,Ao Duan,Hai-Jun Li,Lei Yang,Xiao-Jian Cao

Molecular cancer therapeutics 20:726-738 PubMed33536189

2021

Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-l-glutamic Acid-coated Layer-by-Layer Nanoparticles.

Applications

Unspecified application

Species

Unspecified reactive species

Isidora Tošić,Lisa N Heppler,Susana P Egusquiaguirre,Natalie Boehnke,Santiago Correa,Daniel F Costa,Elizabeth A Grossman Moore,Sharmistha Pal,Douglas S Richardson,Alexander R Ivanov,Daphne A Haas-Kogan,Daniel K Nomura,Paula T Hammond,David A Frank
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com